Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C6H9O15P3.5Na.H |
| Molecular Weight | 530.0047 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@H]1[C@H](O)[C@@H](OP([O-])([O-])=O)[C@H](OP([O-])([O-])=O)[C@H](OP([O-])([O-])=O)[C@@H]1O
InChI
InChIKey=KHSOXCMDPVQTJU-OYJRTZEKSA-I
InChI=1S/C6H15O15P3.5Na/c7-1-2(8)4(19-22(10,11)12)6(21-24(16,17)18)5(3(1)9)20-23(13,14)15;;;;;/h1-9H,(H2,10,11,12)(H2,13,14,15)(H2,16,17,18);;;;;/q;5*+1/p-5/t1-,2-,3+,4-,5-,6-;;;;;/m1...../s1
Atrinositol antagonizes the effect of neuropeptide Y (NPY) in guinea pig basilar arteries. Atrinositol molecule derived from phytic acid. It seems to exert potent protective effects on some of the manifestations associated with diabetes in rats. Atrinositol inhibits glucose-stimulated insulin secretion by a direct effect on the pancreatic islets. Atrinositol appears to modulate fatty acid desaturases and aldose reductase in platelets and delay by a few weeks the development of cataract in this acute model of diabetes. It normalizes platelet aggregation in diabetic animals after long-term administration in vivo.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
136033-48-2
Created by
admin on Mon Mar 31 18:32:49 GMT 2025 , Edited by admin on Mon Mar 31 18:32:49 GMT 2025
|
PRIMARY | |||
|
76961788
Created by
admin on Mon Mar 31 18:32:49 GMT 2025 , Edited by admin on Mon Mar 31 18:32:49 GMT 2025
|
PRIMARY | |||
|
MQS1C50F9A
Created by
admin on Mon Mar 31 18:32:49 GMT 2025 , Edited by admin on Mon Mar 31 18:32:49 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
